Contract Research Organization (CRO) / Contract Development and Manufacturing Organization (CDMO)
Strategic Profile
Operating through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments, the company offers CDRMO services for new drug development from discovery to commercial covering various synthetic molecular modalities including small molecules, oligonucleotides, peptides, and complex conjugates. The company derives key revenue from the United States of America, followed by China, Europe, and other regions.
Cyborg Score Rationale
WuXi AppTec is classified as a Mega Cap company with market caps exceeding $200 billion. The trailing twelve month revenue for WuXi AppTec is $6.15B, demonstrating strong market position. However, recent geopolitical concerns regarding potential military listing inclusion create near-term uncertainty.
Top Insights
Current market capitalization of WuXi AppTec is $40.9B.
WuXi Chemistry segment derives maximum revenue among the four operational divisions
WuXi AppTec Receives Double "A" Rating from CDP for Climate Change and Water Security Leadership (Jan 19, 2026)
Recent strategic expansion into Saudi Arabia market through partnerships with NEOM and Ministry of Health
Named Competitors
BGI Genomics — Genomics research and sequencing services
Pharmaron — Drug discovery and development services
Syngene International — Contract research and manufacturing services
Recent Developments
(January 2026) Received CDP Double "A" rating for climate change and water security leadership
(December 2025) Pentagon consideration for military list adding geopolitical uncertainty
(November 2025) Received Frost & Sullivan's 2025 Global Company of the Year recognition
(October 2025) Signed strategic MoUs with NEOM and Saudi Arabia Ministry of Health for CRDMO platform expansion
Open the full interactive WuXi AppTec Co., Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.